Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ex-vivo Engineered Cell Therapy
Therapeutic Area : Genetic Disease
Study Phase : Discovery Platform
Sponsor : EdiGene
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Partnering with leading engineered cell therapy developers is a key component of Arbor’s strategy to broaden the potential of CRISPR discovery engine beyond the wholly-owned in vivo genetic medicine approaches for the benefit of even more patients.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 08, 2022
Lead Product(s) : Ex-vivo Engineered Cell Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Sponsor : EdiGene
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Enalapril Maleate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Azurity
Deal Size : Undisclosed
Deal Type : Acquisition
Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals
Details : The combined company, operating as Azurity, will have a portfolio of products serving the unmet needs of patients in the cardiovascular, central nervous system, endocrinological, gastrointestinal, and institutional markets with many products like Epaned.
Brand Name : Epaned
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : Enalapril Maleate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Azurity
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase 3 data being presented support Arbor’s New Drug Application (NDA) for AR19, which also includes data demonstrating that AR19 resists manipulation for nonmedical misuse and abuse by non-oral routes of administration.
Brand Name : AR19
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 10, 2020
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?